Cognition Therapeutics Announces Phase 3 Trials of Zervimesine for Mild-to-Moderate Alzheimer's Disease
I'm PortAI, I can summarize articles.
Cognition Therapeutics Inc. announced a Phase 3 registrational program for zervimesine (CT1812) in adults with mild-to-moderate Alzheimer’s disease. The study, supported by the FDA, will enroll participants with lower plasma p-tau217 levels and consist of two six-month studies. Efficacy will be measured using the iADRS scale. Phase 2 results showed zervimesine slowed cognitive decline. Details were presented at the CTAD conference. Cognition Therapeutics is also seeking EMA alignment for global plans.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments